Repare Therapeutics
Repare Therapeutics focuses on synthetic lethality-based precision oncology, using its proprietary SNIPRx® platform to develop targeted cancer therapies. Founded in 2016, the company has a robust pipeline, including Camonsertib, Lunresertib, RP-1664, and RP-3467, and collaborates with Roche for Camonsertib's development and commercialization.
Overview of Repare Therapeutics
Repare Therapeutics, founded in 2016, focuses on synthetic lethality-based precision oncology. This company specializes in discovering and developing cancer therapies that target genomic instability and DNA damage repair. Using its proprietary genome-wide, CRISPR-enabled SNIPRx® platform, Repare Therapeutics identifies novel therapeutic targets to address genetically-defined patient populations.
SNIPRx® Platform
The SNIPRx® platform is a cornerstone of Repare Therapeutics’ research and development efforts. This proprietary genome-wide, CRISPR-enabled platform is pivotal in discovering and developing targeted cancer therapies. It allows for novel target identification and differentiated patient selection insights, enabling the development of a robust portfolio of synthetic lethal therapies.
Development Pipeline
Repare Therapeutics has a diverse development pipeline targeting various mechanisms of DNA repair and genomic instability. Key candidates include Camonsertib, a potential best-in-class ATR inhibitor; Lunresertib, the first PKMYT1 inhibitor to enter clinical trials; RP-1664, a selective Polo-like kinase 4 (PLK4) inhibitor; and RP-3467, a small molecule inhibitor of polymerase theta (Polθ). This comprehensive pipeline reflects Repare Therapeutics' commitment to addressing cancers with high unmet medical needs.
Clinical Trials and Collaborations
Repare Therapeutics conducts extensive clinical trials in the U.S. and other countries to evaluate the efficacy of its therapeutic candidates. Through a collaboration agreement with Roche, Repare aims to develop and commercialize Camonsertib. The ongoing clinical trials and strategic partnerships exemplify Repare Therapeutics’ dedication to advancing precision oncology and bringing targeted cancer therapies to market.
Locations and Facilities
Repare Therapeutics operates from offices and lab spaces located in Cambridge, MA, and Montreal, Quebec. These facilities support the company's research, development, and clinical operations. The presence in these strategic locations enables Repare to leverage local scientific and medical expertise, contributing to its mission of developing innovative cancer therapies.